ARCHIVES

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

This article is from The Cancer Letter archive.

Vol. 25 No. 01 | January 8, 1999

Download PDF Visit The Full Archive

Related Articles

Straus asks to “Set Record Straight”

September 2, 1988

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

September 26, 1997

No Recision Seen, New Money To Low In Mid-March

February 20, 1976

Genitope Therapy In Phase III Trials For Low-Grade B-Cell Non-Hodgkin’s.

October 26, 2001

Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas

December 28, 2012

Highlights of Dingell Hearing: Statements Of Visco, Testimony By Broder On Fisher, Uterine Cancer Deaths

April 22, 1994